Salmonella

抗细菌蛋白质复合物

Absstract of: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

PHAGE LYASE AND USE THEREOF

Absstract of: WO2025227308A1

A phage lyase with an amino acid sequence set forth in SEQ IN NO.2. The lyase can inhibit the growth of Staphylococcus, Escherichia, Klebsiella, and Salmonella bacteria, and can be used as an antibacterial substance in milk pollution control, belonging to the field of bioengineering. The phage lyase can be used for preparing an enzyme formulation alone or in a compounded manner to specifically inactivate bacteria such as Staphylococcus aureus, thereby providing an enzyme formulation source which is safe and free of toxic and side effects for controlling Staphylococcus aureus pollution in milk at present.

弱毒化サルモネラ・チフィムリウム（Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ）を使用する良性神経系腫瘍の処置

Absstract of: US2022125906A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

ANTI-BACTERIAL PROTEIN COMPLEX

Absstract of: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Absstract of: WO2025224621A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

MODIFIED MICROORGANISMS

Absstract of: WO2025224251A1

The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.

VACUOLE ESCAPE

Absstract of: WO2025224268A1

The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.

SYSTEMS, METHODS, AND COMPOSITIONS FOR THE DETECTION OF MICROBES

Absstract of: AU2024264505A1

Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Absstract of: US2025334572A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

METHOD FOR DETECTING FOODBORNE PATHOGENS USING BACTERIOPHAGES

Absstract of: WO2025225874A1

The present invention relates to a method for detecting live foodborne pathogens using novel bacteriophages LEC1, LBC9, and LSE2. By using this method, Escherichia coli, Bacillus cereus, and Salmonella spp., which are live foodborne pathogens in food, can be rapidly and accurately detected at the same time, and thus the method can be effectively used for preventing food poisoning.

METHODS AND SYSTEMS FOR THE RAPID DETECTION OF LISTERIA USING INFECTIOUS AGENTS

Absstract of: EP4641200A2

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

- Recombinant Microbials Expressing Strep-tag and Tumor Imaging Aduvant Comprising the Microbials

Absstract of: KR20240012662A

The present invention relates to a genetic construct characterized in that the anti-sigma factor flgM gene and the gene encoding strep-tag are linked to encode a fusion protein of flgM and strep-tag so that a strep-tag may be expressed on the surface of an anticancer strain that may be targeted to a tumor site and stimulate immune activity, and an anticancer adjuvant and a tumor imaging aid which is transformed thereby and exhibits anticancer activity itself and may be usefully used for the diagnosis and treatment of tumor cells together with an anticancer substance or contrast agent labeled with a substance which specifically reacts with the strep-tag.

BACTERIOPHAGES AND USE THEREOF FOR THE TREATMENT OR PREVENTION OF INFECTION CAUSED BY SALMONELLA GALLINARUM

Absstract of: WO2024137831A2

A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.

一种用于防治多种致病性肠杆菌感染的融合蛋白及应用

Absstract of: CN120842432A

本发明涉及一种应对多种致病性肠杆菌感染防治的融合蛋白、免疫原性组合物、重组简并疫苗，以及分子架构设计和应用等。本发明筛选到3种细胞免疫抗原Tuf、DnaK、fusA，构建的3种抗原的融合蛋白分子可显著抑制多种肠杆菌感染引起的组织病变，具有良好的免疫原性，起到有效防治和免疫保护作用，广谱且高效地预防多种致病性肠杆菌感染，具有广阔的工业应用前景。

免疫原性组合物

Absstract of: WO2024192346A1

Technologies for providing immunogenic compositions (e.g., vaccines) and methods of inducing immune responses in subjects in need thereof.

- Recombinase polymerase amplification primer sets for detecting Salmonella and uses thereof

Absstract of: KR20250151120A

본 발명은 살모넬라(Salmonella) 검출을 위한 재조합효소-중합효소 증폭법(recombinase polymerase amplification)용 프라이머 세트 및 이를 이용한 핵산 측면 흐름 면역 분석(nucleic acid lateral flow immunoassay)용 살모넬라(Salmonella) 검출용 키트에 관한 것으로, 본 발명의 프라이머 세트는 살모넬라(Salmonella)속에 특이적인 유전자인 invA 유전자를 가장 높은 효율로 증폭하여 살모넬라(Salmonella) 검출이 우수할 뿐만 아니라, 재조합효소-중합효소 증폭(recombinase polymerase amplification) 수행시 비교적 낮은 온도에서 짧은 시간안에 증폭이 용의할 뿐만 아니라 상기 프라이머 세트의 역방향 프라이머 말단에 제1 표지물질이 결합하여 검출 가능한 발색입자인 금나노입자가 결합되고, 상기 프라이머 세트가 증폭하는 서열의 일부 서열에 특이적으로 결합하는 부위를 포함하는 프로브는 5' 말단에 제2 표지물질이 결합하여 핵산 측면 흐름 면역 분석(nucleic acid lateral flow immunoassay)에 적용시 RPA 증폭산물을 쉽게 검출 할 수 있는 살모넬라(Salmonella) 검출용 프라이머 세트 및 이의 용도를 제공한다.

DUAL-MODE ELECTROCHEMICAL POINT-OF-CARE DETECTION, QUANTIFICATION AND PROFILING OF PATHOGENS

Absstract of: US2025321227A1

The present invention relates to diagnostic platform. More specifically, the invention relates to a dual platform composed of a detection and quantification unit and a characterization unit, systems, kits, methods and uses thereof in detection, quantification and characterization of pathogens, the system comprising monoclonal-antibody-based biosensor chips, for detection and/or quantification of pathogens in a sample, and substrate-based biosensor chips for enzymatically profiling the pathogen in the sample.

STRUCTURED MICROGEL ELECTROPHORETIC ARRAYS FOR RAPID MULTIPLEX NUCLEIC ACID DETECTION

Absstract of: US2025321205A1

Methods and devices are disclosed for rapid, multiplex molecular detection of diverse nucleic acid target molecules. The invention features an electrophoretic array with immobilized hydrogel microgel deposits. Each deposit comprises a three-dimensional, cross-linked polymer matrix containing an immobilized affinity-binding molecule and a porogen-derived pore network. This structure is configured for rapid molecular transport of nucleic acids (e.g., up to 800 bp), providing a localized environment for target capture, ligation of linear Rolling Circle Amplification (RCA) probes, and RCA. Target-specific components are anchored within distinct microgels for multiplexing. Electric fields enhance transport, reaction kinetics, and amplicon concentration. Detection is achieved in under 20 minutes. The specifically structured and fabricated microgels improve detection speed, sensitivity, and applicability to multiple different targets.

一种提高重组蛋白热稳定性和溶解度的双功能蛋白标签及基于其的产品和应用

Absstract of: CN120757621A

本发明公开了一种提高重组蛋白热稳定性和溶解度的双功能蛋白标签及基于其的产品和应用，属于蛋白工程技术领域。该双功能标签的氨基酸序列SEQ ID NO:1所示，具有70%‑95%以上的相似度，其氨基酸序列变异主要存在但不限于二级结构位置。该双功能标签可在目的蛋白的N端或C端使用，适用于原核表达系统中融合蛋白的表达和纯化。本发明通过理性设计改造天然蛋白的疏水性区域，解决了现有蛋白标签分子量大、易遮蔽目标蛋白活性结构域、标签切除后残留非天然氨基酸可能破坏蛋白正确折叠等技术问题，显著提升融合蛋白在大肠杆菌表达系统中的可溶性及热稳定性，适用于包涵体蛋白的功能性表达与工业化应用。

サルモネラの検出方法

Absstract of: JP2025149945A

【課題】 本発明が解決しようとする課題は、サルモネラの検出を、血清型横断的かつ他の菌種とは特異的に行うことである。【解決手段】サルモネラの加熱死菌体とアジュバントを含む抗原液を、ＢＡＬＢ／ｃマウスに接種した。接種後、マウスの脾細胞またはリンパ節細胞とＰ３Ｕ１とを融合させてハイブリドーマを作製し、その中から、サルモネラ特異性を示すモノクローナルＩｇＧ抗体を産生するハイブリドーマを選抜し、優れたサルモネラ特異性抗体を産生する３つのハイブリドーマを取得することに成功した。次いで、これらのモノクローナル抗体を用いて、サンドイッチＥＬＩＳＡにより複数血清型のサルモネラおよび他の菌種の検出を行ったところ、血清型横断的にサルモネラを検出し、他の菌種を検出しないという結果を得た。【選択図】図１

一种亚单位疫苗及其制备方法与应用

Absstract of: CN120737217A

本发明提供了一种亚单位疫苗及其制备方法与应用。所述疫苗包括式（1）的融合蛋白，D0a‑D1a‑Linker‑HA‑Linker‑D1b‑D0b（1）其中，D0a和D0b分别为细菌鞭毛蛋白FliC的D0结构域或其功能性片段的N端部分和C端部分，D0a和D0b组成细菌鞭毛蛋白FliC的D0结构域或其功能性片段；D1a和D1b分别为细菌鞭毛蛋白FliC的D1结构域或其功能性片段的N端部分和C端部分，D1a和D1b组成细菌鞭毛蛋白FliC的D1结构域或其功能性片段；HA为流感病毒HA蛋白的抗原表位或其功能性片段，linker为连接子，‑为肽键或其他化学键。可以用于流感病毒的净化工作，安全有效，具有较高的应用价值。

A PROCESS FOR PREPARING LACTOBACILLUS-BASED RECOMBINANT VACCINE CANDIDATE AGAINST MULTIPLE SALMONELLA SEROVAR IN POULTRY

Absstract of: WO2025202803A1

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

FIMH INHIBITING COMPOSITIONS AND METHODS OF USE THEREOF

Absstract of: US2025304662A1

Among the various aspects of the present disclosure is the provision of FimH inhibiting compositions and methods of use thereof. FimH inhibiting compositions that target and inhibit FimH, including monoclonal antibodies, are described. Methods of identifying FimH inhibiting antibodies are also described. Further, a method of treating bacterial infections, including urinary tract infections, is described.

ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA

Absstract of: EP4623922A2

The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharmaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.

一种基因工程菌及其在抗革兰氏阴性菌感染中的应用

Nº publicación: CN120718821A 30/09/2025

Applicant:

陕西汇农信创生物科技有限公司

Absstract of: CN120718821A

本发明公开了一种基因工程菌及其在抗革兰氏阴性菌感染中的应用。所述基因工程菌为在出发菌株中利用细菌表面展示系统过表达菌毛黏附素、肠道消化酶识别位点和细菌素。本发明的基因工程菌能在肠道中肠激酶的作用下，释放有活性的细菌素并暴露出菌毛黏附素，并实现杀灭肠道内的鼠伤寒沙门氏菌，及预防鼠伤寒沙门氏菌的再次定植的效果。